Efinaconazole

Efinaconazole (KP-103) is a triazole antifungal agent and againsts T. mentagrophytes SM-110 and C. albicans ATCC 10231 with MICs of 0.0039 μg/mL and 0.00098 μg/mL, respectively[1]. Efinaconazole has a potent in vitro activity against fungal pathogens including dermatophytes, Candida and Malassezia species[1].

Product Specifications

CAS Number

[164650-44-6]

Product Name Alternative

KP-103

UNSPSC

12352005

Hazard Statement

H361

Target

Fungal

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Efinaconazole.html

Concentration

10mM

Purity

99.84

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@@H](N1CCC(CC1)=C)[C@@](O)(C2=CC=C(F)C=C2F)CN3N=CN=C3

Molecular Formula

C18H22F2N4O

Molecular Weight

348.39

Precautions

H361

References & Citations

[1]Tatsumi Y, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May;57 (5) :2405-9.|[2]Tatsum Y, et al. KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002;46 (7) :425-32.